Chronic myelogenous leukemia.

  title={Chronic myelogenous leukemia.},
  author={Brian J. Druker and Charles L Sawyers and Renaud Capdeville and Julia M Ford and Michele Baccarani and John M. Goldman},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  volume={5 5},
The treatment recommendations for chronic myelogenous leukemia (CML) are evolving rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor, have become commercially available and non-myeloablative stem cell transplants continue to be refined. Clinicians and patients face a bewildering array of treatment options for CML. In this article Dr. Sawyer reviews the clinical results with STI571 and ongoing investigations into… CONTINUE READING